Sanofi Debt to Equity Ratio 2010-2024 | SNY
Current and historical debt to equity ratio values for Sanofi (SNY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sanofi debt/equity for the three months ending December 31, 2024 was 0.15.
| Sanofi Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-12-31 |
$59.45B |
$84.25B |
0.71 |
| 2024-09-30 |
$0.00B |
|
0.00 |
| 2024-06-30 |
$61.12B |
$78.61B |
0.78 |
| 2024-03-31 |
$0.00B |
|
0.00 |
| 2023-12-31 |
$56.40B |
$80.47B |
0.70 |
| 2023-09-30 |
$0.00B |
|
0.00 |
| 2023-06-30 |
$57.14B |
$79.54B |
0.72 |
| 2023-03-31 |
$0.00B |
|
0.00 |
| 2022-12-31 |
$54.33B |
$79.18B |
0.69 |
| 2022-09-30 |
$0.00B |
|
0.00 |
| 2022-06-30 |
$53.77B |
$75.88B |
0.71 |
| 2022-03-31 |
$0.00B |
|
0.00 |
| 2021-09-30 |
$0.00B |
|
0.00 |
| 2021-06-30 |
$58.99B |
$76.35B |
0.77 |
| 2021-03-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2019-03-31 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$46.98B |
$65.85B |
0.71 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2017-06-30 |
$48.50B |
$63.58B |
0.76 |
| 2017-03-31 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$51.95B |
$63.88B |
0.81 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$50.57B |
$61.39B |
0.82 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$45.52B |
$62.80B |
0.73 |
| 2014-06-30 |
$53.44B |
$71.01B |
0.75 |
| 2013-06-30 |
$53.27B |
$73.39B |
0.73 |
| 2012-06-30 |
$58.33B |
$72.42B |
0.81 |
| 2012-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2011-12-31 |
$60.97B |
$78.54B |
0.78 |
| 2011-09-30 |
$0.00B |
|
0.00 |
| 2011-06-30 |
$67.62B |
$75.69B |
0.89 |
| 2011-03-31 |
$0.00B |
|
0.00 |
| 2010-12-31 |
$42.46B |
$70.76B |
0.60 |
| 2010-09-30 |
$0.00B |
|
0.00 |
| 2010-06-30 |
$42.97B |
$67.09B |
0.64 |
| 2010-03-31 |
$0.00B |
|
0.00 |
| 2009-12-31 |
$44.07B |
$67.56B |
0.65 |
| 2009-09-30 |
$0.00B |
|
0.00 |
| 2009-06-30 |
$43.55B |
$61.00B |
0.71 |
| 2009-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$138.211B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
